文献速递慢性肾脏病肾小球疾病遗传性与小管间质肾病

量化APOL1、人类白细胞抗原及其他遗传因素对不明原因肾衰竭的贡献

Quantifying APOL1, Human Leukocyte Antigen, and Other Genetic Contributions to Unexplained Kidney Failure.
PubMed 文献 · Am J Kidney Dis · 2025-09-16

研究对218例50岁前发病的不明原因肾衰竭患者行全基因组测序,38例(17%)获单基因诊断;180例未解患者与26373名对照的病例对照分析未额外发现 solved 病例。近期非洲血统者中高风险APOL1基因型在uKF组显著更常见(52% vs 8.4%,P < 0.001)。

要点

  • 全基因组测序在17%(38/218)的不明原因肾衰竭患者中给出单基因诊断。
  • 近期非洲血统者中,高风险APOL1基因型在uKF组占52%,无uKF组占8.4%(P < 0.001)。
  • 病例对照分析未在单基因诊断之外额外发现 solved 病例。

核心结论

  • 全基因组测序在17%的不明原因肾衰竭患者中给出单基因诊断,病例对照分析未额外发现 solved 病例。
  • 研究结果强调APOL1在近期非洲血统者中的作用,并提示其遗传结构与常见慢性肾脏病不同。

研究设计与样本

  • 研究招募英国100,000 Genomes Project中218例50岁前发病的不明原因肾衰竭患者,行全基因组测序并由多学科团队审核候选致病变异。
  • 对临床分析后仍未解决的180例uKF患者(非单基因uKF队列)行基于基因和结构变异的关联分析,并以26373名非肾脏先证者的未患病亲属为对照。
  • 评估537个基因的候选变异(结构变异和单变异水平)、高风险APOL1基因型及慢性肾脏病和各种肾小球疾病的多基因风险评分。

主要发现

  • 218例中38例(17%)通过100,000 Genomes Project临床臂的全基因组测序获得单基因诊断。
  • uKF中位发病年龄为36岁,≥36岁患者诊断频率较低,与家族史无关。
  • 无家族史的三例老年患者携带IV型胶原基因致病变异。
  • 近期非洲血统者中,高风险APOL1基因型在uKF组占52%,无uKF组占8.4%(P < 0.001)。
  • 在高风险APOL1基因型且uKF者中观察到类固醇敏感性肾病综合征多基因风险评分升高,部分源于HLA-DQB1∗03:19位点差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出潜在局限性包括亚组样本量小和使用短读长全基因组测序。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Unexplained kidney failure (uKF) affects 15% of individuals needing kidney replacement therapy. The lack of a clear diagnosis creates uncertainty about recurrence, familial risk, and trial eligibility. This study sought to identify genetic variants underlying uKF. STUDY DESIGN: Genomic analyses conducted using whole-genome sequencing (WGS) were reviewed by a multidisciplinary team that identified candidate pathogenic variants. A case-control study was implemented for single and structural variants to perform gene-based and polygenic risk score (PRS) association testing. SETTING & PARTICIPANTS: The study recruited 218 patients with uKF onset before age 50 years from the United Kingdom's 100,000 Genomes Project. Association analysis was performed in 180 uKF cases that remained unsolved after clinical analysis and constituted the nonmonogenic uKF cohort. 26,373 control subjects were derived from the unaffected relatives of nonrenal probands. EXPOSURES: Candidate variants in 537 genes were assessed at a structural and single-variant level in the 218 recruited patients, as were high-risk APOL1 genotypes and PRSs for chronic kidney disease and various glomerular diseases. OUTCOMES: The primary outcomes were establishing a genetic diagnosis and the associations between genetic findings, age, family history, and ancestry. ANALYTICAL APPROACH: Candidate variants were reviewed for pathogenicity. Gene-based and structural variant analyses and high-risk APOL1 genotype assessments were performed. PRSs and post hoc HLA associations were also investigated. RESULTS: Monogenic diagnoses were made in 38 of 218 patients (17%) using WGS via the clinical arm of the 100,000 Genomes Project. Median uKF onset was at the age of 36 years. Diagnoses were less frequent in patients aged ≥36 years, irrespective of family history. Three older patients without a family history had pathogenic variants in type IV collagen genes. Among individuals with recent African ancestry, high-risk APOL1 genotypes were significantly more common in those with uKF (52% vs 8.4% in those without uKF; P < 0.001). An increased steroid-sensitive nephrotic syndrome PRS was observed in those with high-risk APOL1 genotypes and uKF, partly due to differences at HLA-DQB1∗03:19. LIMITATIONS: Potential limitations include the small sizes of subgroups and use of short-read WGS. CONCLUSIONS: WGS yielded a monogenic diagnosis in 17% of patients with uKF, with no additional solved cases arising from the case-control analysis. These findings underscore APOL1's role in those with recent African ancestry and suggest a genetic architecture distinct from common chronic kidney disease. PLAIN-LANGUAGE SUMMARY: Our study was motivated by the difficulty in understanding why some people experience kidney failure (KF) without a clear cause. Many patients face uncertainty about their future health and treatment because doctors cannot always find an explanation for their condition. To address this challenge, we examined the complete genetic blueprint of individuals with unexplained KF. We looked for genetic clues that might reveal hidden risks. Our work uncovered specific genetic factors that appear to contribute to KF, especially among people with African heritage. These insights are important because they may help explain why KF happens in some cases and inform personalized diagnosis and treatment.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Sadeghi-Alavijeh O, Chan MMY, Tzoumkas K, et al. Quantifying APOL1, Human Leukocyte Antigen, and Other Genetic Contributions to Unexplained Kidney Failure. Am J Kidney Dis. 2025. PMID: 40967557. doi:10.1053/j.ajkd.2025.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。